Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer to Acquire Biohaven Pharmaceuticals
From Pfizer Inc.
Via Business Wire
Tickers BHVN PFE
Pfizer Reports First-Quarter 2022 Results
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares Second-Quarter 2022 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
From Pfizer Inc.
Via Business Wire
Tickers BHVN PFE
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE VALN
Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Names David M. Denton Chief Financial Officer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
From Pfizer Inc.
Via Business Wire
Tickers OPK PFE
European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports Fourth-Quarter and Full-Year 2021 Results
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces New Chief Development Officer
From Pfizer Inc.
Via Business Wire
Tickers PFE
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
From Pfizer Inc.
Via Business Wire
Tickers OPK PFE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.